Gliclazide + Metformin Tablets(Er) Suppliers & Bulk Manufacturers
Available Forms: Tablets(ER)
Available Strengths: Gliclazide 30 mg/60 mg + Metformin 500/1000 mg
Reference Brands: Glizid-M XR(US & EU)
Category:
Diabetes
Gliclazide, a sulfonylurea, stimulates insulin secretion from pancreatic β-cells, while Metformin decreases hepatic glucose production and improves insulin sensitivity. This extended-release combination ensures stable blood glucose levels, reduces postprandial spikes, and improves patient adherence through once-daily dosing—offering synergistic control for type 2 diabetes with a lower risk of hypoglycemia.
Gliclazide + Metformin Tablets(ER) is available in Tablets(ER)
and strengths such as Gliclazide 30 mg/60 mg + Metformin 500/1000 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Gliclazide + Metformin Tablets(ER) is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Gliclazide + Metformin Tablets(ER) can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Gliclazide + Metformin Extended-Release (ER) tablets are not FDA-approved in the United States but are widely authorized and marketed in the European Union under national procedures. The combination is indicated for managing type 2 diabetes mellitus in adults inadequately controlled on monotherapy. Products are registered under well-known brands like Diamicron MR + Metformin XR. European regulatory agencies mandate bioequivalence, stability, and pharmacodynamic evidence to ensure safety and efficacy. Although not listed in the U.S. Orange Book, this fixed-dose combination supports enhanced patient compliance and glycemic control. For sourcing support and B2B pharmaceutical trade, visit Pharmatradz.com.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing